Transforming growth factor beta 1 signaling pathway (via Smad2 and Smad3) (TGF-β1/Smad2/3 pathway)

The Transforming growth factor beta 1/Smad2/3 signaling pathway is a canonical signal transduction cascade initiated by TGF-β1 ligand binding to a heteromeric receptor complex (type I and type II TGF-β receptors), resulting in phosphorylation of receptor-activated SMADs (SMAD2 and SMAD3), which then form complexes with SMAD4, translocate to the nucleus, and regulate transcription of target genes. This pathway governs broad cellular functions including proliferation, differentiation, apoptosis, immune homeostasis, and epithelial-mesenchymal transition. The pathway displays context-dependent tumor-suppressive and tumor-promoting activity, and is implicated in various disease processes including cancer, fibrosis, cardiovascular, and immune diseases[7][6][2][3][4][5][1]. Targeting individual components (commonly the receptors or ligand) is under active clinical investigation, but broad pathway inhibition carries significant safety risks.

Other names

TGF-beta/Smads pathwayTGF-β/Smad signalingTGF-β1 pathway

Inhibition of TGF-β ligand binding to receptors; Blockade of TGF-β receptor serine/threonine kinase activity; Inhibition of SMAD2/3 phosphorylation and nuclear translocation; Neutralization of TGF-β ligand